MedPath

Valbenazine

Generic Name
Valbenazine
Brand Names
Ingrezza
Drug Type
Small Molecule
Chemical Formula
C24H38N2O4
CAS Number
1025504-45-3
Unique Ingredient Identifier
54K37P50KH
Background

Valbenazine is a modified metabolite of tetrabenazine, and it is currently being approved for the treatment of various movement disorders, particularly tardive dyskinesia and chorea associated with Huntington's disease. Tardive dyskinesia has long been regarded as a consequence of anti-dopamine receptor therapy, and until 2008 with the advent of tetrabenazine, most treatments were ineffective. However, challenges in using tetrabenazine as a treatment of tardive dyskinesia included frequent dosing and safety and tolerability concerns.

On April 2017, valbenazine was approved by the FDA under the brand name INGREZZA as the first and only approved treatment for adults with Tardive Dyskinesia (TD). On August 2023, valbenazine was again approved by the FDA for the treatment of chorea associated with Huntington's disease respectively. This approval was supported by positive results in multiple trials, including the KINECT-HD Phase 3 study and the ongoing KINECT-HD2 open-label extension trial. The reduction in chorea severity was observed as early as 2 weeks after starting treatment with an initial dose of 40 mg.

Indication

Valbenazine is indicated for the treatment of adults with tardive dyskinesia and chorea associated with Huntington’s disease.

Associated Conditions
Chorea, Tardive Dyskinesia (TD)
Clinical Trials
Related News

Neurocrine Biosciences Appoints Dr. Sanjay Keswani as New Chief Medical Officer

• Neurocrine Biosciences has appointed Dr. Sanjay Keswani as Chief Medical Officer effective June 2, 2025, succeeding Dr. Eiry W. Roberts who served in the role for seven years. • Dr. Keswani brings over 20 years of pharmaceutical industry experience as a physician-scientist with expertise across multiple therapeutic areas and will lead clinical development and medical affairs activities. • Prior to joining Neurocrine, Dr. Keswani served as President and CEO of ImmunoBrain and held senior leadership positions at Hoffman La Roche and Bristol-Myers Squibb.

Phase 4 KINECT-PRO Trial Shows Ingrezza Significantly Improves Quality of Life in Tardive Dyskinesia Patients

• Neurocrine Biosciences' phase 4 KINECT-PRO study demonstrates sustained improvements in physical, social, and emotional impacts of tardive dyskinesia with Ingrezza treatment across all severity levels. • The 24-week trial showed significant patient-reported benefits starting as early as 4 weeks at the lowest dose (40mg), with 52 out of 59 enrolled patients completing the study. • Results revealed consistent efficacy regardless of underlying psychiatric conditions, with improvements measured across multiple validated clinical scales including AIMS and TD Impact Scale.

FDA Grants Fast Track Status to Neuren's Novel Pitt Hopkins Syndrome Treatment

• Neuren Pharmaceuticals receives FDA Fast Track designation for their investigational treatment targeting Pitt Hopkins syndrome, a rare neurodevelopmental disorder affecting 1 in 34,000-41,000 people. • The Fast Track status aims to expedite the development and review process for this potential first-ever approved treatment for Pitt Hopkins syndrome. • Company shares responded positively to the announcement, rising 5.4% to $13.77, marking a significant development in addressing this serious unmet medical need.

Mizuho Securities Maintains Hold Rating on Neurocrine as Osavampator Development Faces Timeline Uncertainties

Mizuho Securities analyst Uy Ear has maintained a Hold rating on Neurocrine Biosciences (NBIX) amid concerns over osavampator's development timeline and financial obligations. The Phase 3 trials for the major depressive disorder (MDD) treatment are facing delays until 2025, while royalty agreements with Takeda add financial complexity to the drug's market potential.

Schizophrenia Market Set for Strong Growth, Driven by Novel Therapies

• The schizophrenia market is expected to grow significantly, driven by the launch of novel therapies and increased diagnosis rates. • Long-acting injectables (LAIs) are gaining traction despite higher costs, offering an alternative to oral antipsychotics. • The US dominates the schizophrenia market due to a large patient population and high drug costs. • Emerging treatments like Cobenfy, evenamide, Ingrezza, and iclepertin aim to address unmet needs in managing both positive and negative symptoms.

AI-Discovered Drug SOM3355 Shows Promise in Treating Huntington's Disease

SOM Biotech's AI-discovered drug, SOM3355, has shown promising results in a phase 2 trial for Huntington's disease, significantly improving symptoms of chorea. The drug, originally developed for high blood pressure, could offer a new treatment option with fewer side effects compared to existing medications.

Neurocrine Biosciences' Crenessity Receives FDA Approval for Congenital Adrenal Hyperplasia

• The FDA has approved Neurocrine Biosciences' Crenessity for treating classic congenital adrenal hyperplasia (CAH) in adults and pediatric patients. • Crenessity is the first corticotropin-releasing factor type 1 receptor (CRF1) antagonist to directly reduce excess adrenocorticotropic hormone (ACTH) and adrenal androgen production. • Goldman Sachs increased Neurocrine's price target to $182, maintaining a Buy rating, citing the approval as a major validation for the company's drug development capabilities. • Crenessity's commercial launch is expedited to the end of this week, and analysts will monitor patient adoption, insurance coverage, and clinical experiences to evaluate its progress.

J&J's Icotrokinra Achieves Phase III Success in Psoriasis Treatment

• Johnson & Johnson's icotrokinra demonstrated significant skin clearance and tolerability in Phase III trials for psoriasis treatment. • The oral, once-daily pill could offer an industry-leading combination of efficacy and safety for patients. • Icotrokinra's success positions it as a potential novel treatment option in the psoriasis market, addressing unmet needs.

Valbenazine Demonstrates Sustained Efficacy in Huntington's Chorea Treatment

• Interim data from the KINECT-HD2 study shows valbenazine provides sustained, clinically meaningful improvements in Huntington's disease chorea for up to one year. • Improvements in Total Maximal Chorea scores were observed as early as week 2 and sustained through week 50, regardless of concomitant antipsychotic treatment. • The most common treatment-emergent adverse events were falls, fatigue, and somnolence, with a discontinuation rate of 13.6% due to these events. • Valbenazine, initially approved for tardive dyskinesia, received expanded approval for Huntington's chorea in 2023 based on KINECT-HD study results.
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy